Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


0.5 stars

299 Reads | 0 Comments | 0 People call this a favourite


  • T.PLI:IR comments on the 50M$ financing...

    228 Reads | 1 Comment | 1 day ago

    Here is Fred's answerers to a couple of questions I had about the recent financing announcement. Hi Doug, To the contrary, things are going on very well at PLI. The financing was rendered necessary for a few reasons:   1- We needed to have a balance sheet and a cash position that is more in line with our market cap, compared to our peers and with industry standards for a...

  • T.PLI:BNN: we're top pick #1

    195 Reads | 0 Comments | March 19, 2015

    TOP Pick Today

  • T.PLI:article:PLI celebrates diabetic kidney disease drug milestone

    247 Reads | 1 Comment | September 3, 2014

    ProMetic Life Sciences (T.PLI) celebrates diabetic kidney disease (DKD) drug milestone   ProMetic Life Sciences (TSX: PLI, Stock Forum) celebrated another important milestone in the regulatory journey for its anti-fibrotic, lead drug candidate, PBI-4050, when the company announced today that it had a successful Pre-Investigational New Drug (“Pre-IND”) meeting with the...

  • T.PLI:BNN/market call comments, aug 29

    315 Reads | 1 Comment | September 2, 2014

    Top Picks: Prometic Life Sciences (PLI.TO 1.48 0.00 0.00%) Prometic is a manufacturing company with the bonus of PBI-4050 ,an interesting drug discovery. PLI has proprietary filtering technology used for large scale purification of drugs and is using this technology to extract proteins from plasma at their plant in Laval, Quebec. Clinical studies of three proteins...

  • T.PLI:PLI on BNN/market call

    297 Reads | 0 Comments | August 29, 2014 about the 2 minute mark

  • T.PLI:cantech letter:PLI offers compelling risk/reward scenario, says Paradigm

    559 Reads | 0 Comments | August 28, 2014

    Prometic Life Sciences offers compelling risk/reward scenario, says Paradigm   August 20, 2014 By Nick Waddell 0 Comments Share this: 2 0 0 ProMetic Life Sciences (TSX:PLI) offers a truly compelling risk/reward scenario, says Paradigm Capital analyst Alan Ridgeway. Last Thursday, ProMetic reported its Q2, 2014 results. The company posted revenue of $4.4-million,...

  • T.PLI:and now inside buying...

    214 Reads | 0 Comments | August 27, 2014 Latest 10 SEDI filings (by transaction date) for PLI within the last 6 months [?] Amended Filing   As of 11:59pm ET August 26th, 2014 Filing Date Transaction Date Insider Name Ownership Type Securities ...

  • T.PLI:Beacon full report:price target 3.50$

    231 Reads | 0 Comments | August 25, 2014

    aug 18, Beacon, full new report, price target 3.50$   link:   2$+  for sur very near term... if buy out AT LEAST 4$+.... near term.....